Pulmonary hypertension (PH) is a complex, multifactorial disease characterized by elevated pulmonary artery pressure. This article provides an overview of the disease's pathophysiology, diagnostic approaches, and treatment options.
PH is a hemodynamic and pathophysiological condition defined by an increase in mean pulmonary arterial pressure ≥ 25 mmHg at rest. This condition can lead to right heart failure and death if left untreated. The disease's pathophysiology involves three major processes: vasoconstriction, vascular remodeling, and thrombosis.
Diagnosing PH requires a high index of suspicion. Initial diagnostic procedures include echocardiography and right heart catheterization. Echocardiography is used to estimate pulmonary artery pressure, while right heart catheterization confirms the diagnosis. Other diagnostic tools such as computed tomography (CT), magnetic resonance imaging (MRI), and ventilation-perfusion (V/Q) scan may also be used to determine the underlying cause.
Treatment of PH is tailored based on the underlying cause, disease severity, and patient's overall health. Current therapeutic strategies aim to improve symptoms, slow disease progression, and improve survival. These include general measures (oxygen therapy, diuretics), targeted PH therapies (endothelin receptor antagonists, phosphodiesterase type 5 inhibitors, prostacyclin analogs), and advanced therapies (atrial septostomy, lung transplantation).
In conclusion, PH is a complex disease requiring a comprehensive understanding of its pathophysiology, diagnosis, and treatment. Early recognition and prompt initiation of appropriate therapy can significantly improve patient outcomes. As healthcare professionals, it is our responsibility to stay abreast with the latest developments in the field to provide optimal care to our patients.
1.
Can Prior Authorization Be Better With Artificial Intelligence?
2.
How a California Oncologist Making $850k Spends Money
3.
DNA's hidden shape reveals target to reverse ovarian cancer chemoresistance
4.
Extended Maintenance with Imatinib Enhances Disease-Free Survival in High-Risk GIST.
5.
Because of the Medicare mail-order drug rule, oncologists run the risk of self-referral violations.
1.
Unveiling the Hidden Dangers of Hand Cancer: How to Protect Yourself
2.
Uncovering the Mysteries of Breast Cancer: The Journey to a Cure
3.
Erythropoiesis Modulation in Chronic Anemia Management
4.
Comprehensive Concepts in Oncology in Clinical Decision-Making
5.
Precision Cancer Risk Mitigation Strategies
1.
International Conference on Innovations in Critical Care for Oncology and Cardiology
2.
International Conference on Oncology, Cardiology and Critical Care Policy
3.
International Conference on Oncology, Cancer Prevention and Public Health
4.
International Conference on Cancer Nursing and Rehabilitation Strategies
5.
International Conference on Best Practices in Oncology, Cardiology and Critical Care
1.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Q & A Session
2.
Guideline Recommendations of Lorlatinib as First-Line Treatment for ALK+ NSCLC
3.
Managing Supportive Care During Platelet Recovery
4.
An In-Depth Look At The Signs And Symptoms Of Lymphoma- The Conclusion
5.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation